Larotrectinib for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Dec 2015: Trial started, NCT02637687
  2. 22 Dec 2015: Trial registered, NCT02637687

The trials

NCT02637687: A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

State
Under way
Phase
Phase 1 and Phase 2
People
154 taking part
Started
16 Dec 2015
Primary completion
20 Jul 2024
Arms
Phase 1 dose escalation, Phase 1 dose expansion, Phase 2: Patients with tumors bearing NTRK fusions (IFS)_Cohort 1, Phase 2: Other extra-cranial solid tumors_Cohort 2, Phase 2: Primary CNS tumors_Cohort 3, Phase 2: Bone health assessment_sub-cohort
Results
None posted
  1. 16 Dec 2015: Trial started
  2. 22 Dec 2015: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Larotrectinib (Vitrakvi, BAY2757556).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.